{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"319.8","upperLimit":"637.8","value":"451.6"},{"groupId":"OG001","lowerLimit":"599.9","upperLimit":"990.6","value":"770.9"},{"groupId":"OG002","lowerLimit":"1237","upperLimit":"2087","value":"1607"},{"groupId":"OG003","lowerLimit":"1716","upperLimit":"2826","value":"2202"},{"groupId":"OG004","lowerLimit":"153.1","upperLimit":"1654","value":"503.1"},{"groupId":"OG006","lowerLimit":"1451","upperLimit":"2407","value":"1869"},{"groupId":"OG007","lowerLimit":"1518","upperLimit":"2207","value":"1830"},{"groupId":"OG008","lowerLimit":"1414","upperLimit":"2437","value":"1857"},{"groupId":"OG009","lowerLimit":"858.9","upperLimit":"1442","value":"1113"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"23"},{"groupId":"OG003","value":"13"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"22"},{"groupId":"OG007","value":"22"},{"groupId":"OG008","value":"14"},{"groupId":"OG009","value":"13"}],"units":"Participants"}],"description":"Area under the concentration-time curve from time 0 extrapolated to infinity, calculated as AUC0-t + last observed concentration (Clast)/terminal rate constant (λz), using the Linear up/Log down method.\n\nTerminal rate constant (λz).","dispersionType":"95% Confidence Interval","groups":[{"description":"Pimasertib (MSC1936369B) capsule administered at a single oral dose of 15 milligram (mg) on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DE Cohort).","id":"OG000","title":"Pimasertib (MSC1936369B) 15mg"},{"description":"Pimasertib (MSC1936369B) capsule administered at a single oral dose of 30 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DE Cohort).","id":"OG001","title":"Pimasertib (MSC1936369B) 30mg"},{"description":"Pimasertib (MSC1936369B) capsule administered at a single oral dose of 60 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DE Cohort).","id":"OG002","title":"Pimasertib (MSC1936369B) 60mg"},{"description":"Pimasertib (MSC1936369B) capsule administered at a single oral dose of 90 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DE Cohort).","id":"OG003","title":"Pimasertib (MSC1936369B) 90mg"},{"description":"Pimasertib (MSC1936369B) capsule administered twice, orally, at a dose of 45 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DE Cohort).","id":"OG004","title":"Pimasertib (MSC1936369B) 45mg Twice Daily"},{"description":"Pimasertib (MSC1936369B) capsule administered twice, orally, at a dose of 60 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DE Cohort).","id":"OG005","title":"Pimasertib (MSC1936369B) 60mg Twice Daily"},{"description":"Pimasertib (MSC1936369B) capsule administered at a single oral dose of 60 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DSE Cohort).","id":"OG006","title":"TNBC: Pimasertib 60mg Once Daily"},{"description":"Pimasertib (MSC1936369B) capsule administered at a single oral dose of 60 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DSE Cohort).","id":"OG007","title":"NSCLC: Pimasertib 60mg Once Daily"},{"description":"Pimasertib (MSC1936369B) capsule administered at a single oral dose of 60 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DSE Cohort).","id":"OG008","title":"CRC: Pimasertib 60mg Once Daily"},{"description":"Pimasertib (MSC1936369B) capsule administered at a single oral dose of 60 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DSE Cohort).","id":"OG009","title":"MEL: Pimasertib 60mg Once Daily"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"The PK analysis set. Here \"N\" signifies the number of subjects evaluable for this outcome measure. Data was not available for 'Pimasertib (MSC1936369B) 60mg Twice Daily' arm as no subjects were considered evaluable because of limited number of samples collected to characterize the terminal phase rate constant needed for the calculation of AUCinf.","reportingStatus":"POSTED","timeFrame":"Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1 for DE cohorts","title":"Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC 0-inf) of Pimasertib (MSC1936369B) at Day 1","type":"SECONDARY","unitOfMeasure":"hr*ng/mL"}